As of the data cutoff date, objective responses were observed in patients with HER2-postive breast cancer at dose levels of 1.0 mg/kg and higher, and responses were also observed in some patients with HER2-low breast cancer and non-breast cancer patients. Here, ERBB2 is linked to breast carcinoma.